These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

620 related items for PubMed ID: 15828836

  • 21. Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.
    Bruno RD, Vasaitis TS, Gediya LK, Purushottamachar P, Godbole AM, Ates-Alagoz Z, Brodie AM, Njar VC.
    Steroids; 2011 Nov; 76(12):1268-79. PubMed ID: 21729712
    [Abstract] [Full Text] [Related]

  • 22. Steroid derivatives as pure antagonists of the androgen receptor.
    Gauthier S, Martel C, Labrie F.
    J Steroid Biochem Mol Biol; 2012 Oct; 132(1-2):93-104. PubMed ID: 22449547
    [Abstract] [Full Text] [Related]

  • 23. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.
    Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS.
    Mol Endocrinol; 1997 Apr; 11(4):450-9. PubMed ID: 9092797
    [Abstract] [Full Text] [Related]

  • 24. A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.
    Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, Briere D, Los G, Gleave M, Fanjul A, Zoubeidi A.
    Mol Cancer Ther; 2013 May; 12(5):567-76. PubMed ID: 23493310
    [Abstract] [Full Text] [Related]

  • 25. Identification of steroid derivatives that function as potent antiandrogens.
    Miyamoto H, Marwah P, Marwah A, Yang Z, Chung CY, Altuwaijri S, Chang C, Lardy H.
    Int J Cancer; 2005 Dec 10; 117(5):866-72. PubMed ID: 15981214
    [Abstract] [Full Text] [Related]

  • 26. Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.
    Norris JD, Ellison SJ, Baker JG, Stagg DB, Wardell SE, Park S, Alley HM, Baldi RM, Yllanes A, Andreano KJ, Stice JP, Lawrence SA, Eisner JR, Price DK, Moore WR, Figg WD, McDonnell DP.
    J Clin Invest; 2017 Jun 01; 127(6):2326-2338. PubMed ID: 28463227
    [Abstract] [Full Text] [Related]

  • 27. Antiandrogenic mechanisms of pesticides in human LNCaP prostate and H295R adrenocortical carcinoma cells.
    Robitaille CN, Rivest P, Sanderson JT.
    Toxicol Sci; 2015 Jan 01; 143(1):126-35. PubMed ID: 25324206
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Pharmacokinetics of novel inhibitors of androgen synthesis after intravenous administration in mice.
    Nnane IP, Njar VC, Brodie AM.
    Cancer Chemother Pharmacol; 2003 Jun 01; 51(6):519-24. PubMed ID: 12715204
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Tanshinones from Chinese medicinal herb Danshen (Salvia miltiorrhiza Bunge) suppress prostate cancer growth and androgen receptor signaling.
    Zhang Y, Won SH, Jiang C, Lee HJ, Jeong SJ, Lee EO, Zhang J, Ye M, Kim SH, Lü J.
    Pharm Res; 2012 Jun 01; 29(6):1595-608. PubMed ID: 22281759
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Design and synthesis of androgen receptor full antagonists bearing a p-carborane cage: promising ligands for anti-androgen withdrawal syndrome.
    Goto T, Ohta K, Fujii S, Ohta S, Endo Y.
    J Med Chem; 2010 Jul 08; 53(13):4917-26. PubMed ID: 20521823
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer.
    Han D, Gao S, Valencia K, Owiredu J, Han W, de Waal E, Macoska JA, Cai C.
    Oncotarget; 2017 Jan 24; 8(4):6796-6808. PubMed ID: 28036278
    [Abstract] [Full Text] [Related]

  • 39. Antiandrogenic, maspin induction, and antiprostate cancer activities of tanshinone IIA and its novel derivatives with modification in ring A.
    Liu W, Zhou J, Geng G, Shi Q, Sauriol F, Wu JH.
    J Med Chem; 2012 Jan 26; 55(2):971-5. PubMed ID: 22175694
    [Abstract] [Full Text] [Related]

  • 40. New steroidal oxazolines, benzoxazoles and benzimidazoles related to abiraterone and galeterone.
    Latysheva AS, Zolottsev VA, Veselovsky AV, Scherbakov KA, Morozevich GE, Pokrovsky VS, Novikov RA, Timofeev VP, Tkachev YV, Misharin AY.
    Steroids; 2020 Jan 26; 153():108534. PubMed ID: 31678134
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.